EAACI guidelines on allergen immunotherapy: Executive statement

Muraro, Antonella; Roberts, Graham; Halken, Susanne; Agache, Ioana; Angier, Elisabeth; Fernández-Rivas, M; Wijk, R. Gerth van; Jutel, Marek; Lau, Susanne; Pajno, Giovanni Battista; Pfaar, Oliver; Ryan, Dermot; Sturm, Gunter J.; Ree, Ronald van; Varga, Éva; Bachert, Claus; Calderón, Moisés A.; Canonica, Giorgio Walter; Durham, Stephen R.; Malling, Hans‐Jørgen; Wahn, Ulrich; Sheikh, Aziz

doi:10.1111/all.13420

Cited by 132 publications

(150 citation statements)

References 9 publications

(5 reference statements)

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Seasonal and perennial allergens can be inhaled and ingested and can enter the body via the injured skin and induce an IgE‐mediated local or systemic inflammatory process . Currently, allergen‐specific immunotherapy (AIT) is the only curative treatment that induces clinical and immunological tolerance to causative allergens in allergic patients . AIT efficiently decreases symptoms of allergic asthma, rhinitis, and insect sting allergy .…”

Section: Introductionmentioning

confidence: 99%

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Boonpiyathad

Sokołowska

Morita

et al. 2019

Allergy

View full text Add to dashboard Cite

Background: Allergen-specific immunotherapy (AIT) is the only available treatment for allergic diseases that can induce specific immune tolerance to allergens. The key mechanisms involved in this process include changes in allergen-specific regulatory T (Treg) cells. Methods:We studied 25 allergic rhinitis patients undergoing subcutaneous house dust mite-specific immunotherapy. Peripheral blood mononuclear cells were studied before and after 10, 30 weeks, and 3 years of AIT. Der p 1-specific T regulatory cell responses were investigated by characterization of Der p 1-MHC class II tetramerpositive cells and correlated with nasal symptom score. Results: Twelve of 25 AIT patients matched with their MHC class II expression to the Der p 1 peptide-MHC class II tetramers. A significant increase in the numbers of Der p 1-specific FOXP3 + Helios + CD25 + CD127 − Treg cells after 30 weeks was observed, which slightly decreased after 3 years of AIT. In contrast, Der p 1-specific immunoglobulin-like transcript 3 (ILT3) + CD25 + Treg cells decreased substantially from baseline after 3 years of AIT. ILT3 + Treg cells displayed compromised suppressive function and low FOXP3 expression. In addition, Der p 1-specific IL-10 and IL-22 responses have increased after 30 weeks, but only IL-10 + Der p 1-specific Treg cells remained present at high frequency after 3 years of AIT. Increased number of FOXP3 + Helios + and IL-10 + and decreased ILT3 + Treg cell responses correlated with improved allergic symptoms. Conclusion: The results indicate that AIT involves upregulation of the activated allergen-specific Treg cells and downregulation of dysfunctional allergen-specific Treg cell subset. Correction of dysregulated Treg cells responses during AIT is associated with improved clinical response. K E Y W O R D Sallergen-specific T cells, antigen-specific immunotherapy, house dust mite allergy, Treg Abbreviations: AIT, antigen-specific immunotherapy; AR, allergic rhinitis; HDM, house dust mite; ILT3, immunoglobulin-like transcript 3; Treg, T regulatory.

show abstract

Section: Introductionmentioning

confidence: 99%

Der p 1‐specific regulatory T‐cell response during house dust mite allergen immunotherapy

Boonpiyathad

Sokołowska

Morita

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…There is ongoing research into alternative methods, such as the intermittent administration of beclomethasone in children. 94 Tiotropium has been recently demonstrated to be a safe add-on therapy of inhaled corticosteroids in children aged [6][7][8][9][10][11] with symptomatic moderate asthma and its pharmacokinetic parameters were similar to those obtained in adolescents and adults. 95 After mites and pollens, animals are the third leading cause of allergic asthma.…”

Section: A S Thma Tre Atmentmentioning

confidence: 67%

“…118 The levels of HDM-reactive T-cell subsets, ST2 + CD45RO + CD4 + and IL-5 + IL-13 + CD27 − CD161 + CD4 + , from PBMCs are reduced after 1 year of HDM SLIT and may be used as biomarkers of a positive therapeutic outcome. 119 Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project 5 The international WAO/EAACI guideline for the management of hereditary angioedema -the 2017 revision and update 8 Allergen immunotherapy in people, dogs, cats and horses -differences, similarities and research needs 9 EAACI guidelines on allergen immunotherapy: Executive statement 10 EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy 11 EAACI guidelines on allergen immunotherapy: Allergic rhinoconjunctivitis 15 Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy 16 Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force 17 EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy 18 Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI position paper 123 Promoting and achieving excellence in the delivery of Integrated Allergy Care: the European Academy of Allergy & Clinical Immunology competencies for allied health professionals working in allergy 103 The urgent need for a harmonized severity scoring system for acute allergic reactions 127 Current practice of allergy diagnosis and the potential impact of regulation in Europe 128 EAACI/ENDA Position Paper: Diagnosis and management of hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) in children and adolescents 129 Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications 130 The roadmap for allergology in Europe: The subspecialty of allergology as "stop-over" on the way to a full specialty. An EAACI position statement seasonal AR.…”

Section: Allerg En Immunother Apy ( Ait )mentioning

confidence: 99%

“…asthma, and food allergy in 2016 1,2 and 2017. 3 EAACI published allergen-specific immunotherapy guidelines (AIT) in 2018, [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] and there have been extensive literature reviews and meta-analyses on the subject. [19][20][21][22][23][24] Allergic diseases and asthma concern over 25% of the European population and cause a very high socio-economic burden.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Highlights and recent developments in airway diseases in EAACI journals (2018)

Bousquet

Akdiş

Grattan

et al. 2019

Allergy

Self Cite

View full text Add to dashboard Cite

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta‐analyses.

show abstract

“…11 2.2 | Step 2: Specific AR treatment recommendations From these 13 major scenarios, 34 detailed scenarios were developed. Recommendations on the benefits and use of AIT may be found elsewhere.…”

Section: Step 1: Major Scenarios On Ar Management Approachmentioning

confidence: 99%